Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia

Clinical Science

Volumn 122, Issue 2, 2012, Pages 43-52

  Verlohren, Stefan ^a   Stepan, Holger ^b   Dechend, Ralf ^c,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d HELIOS Clinic Berlin Buch   (Germany)

Author keywords

Angiogenesis; Growth factor; Placental growth factor (PLGF); Pre eclamspsia; Soluble Fms like tyrosine kinase 1 (sFlt 1); Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENIC FACTOR; ANGIOGENIC PROTEIN; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD PRESSURE MEASUREMENT; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; DISEASE PREDISPOSITION; FEMALE; NEOVASCULARIZATION (PATHOLOGY); PLACENTA; PREGNANCY; VASCULARIZATION;

ANGIOGENIC PROTEINS; BIOLOGICAL MARKERS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 80555143068     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110097     Document Type: Review

References (105)

1. Brown, M. A., Lindheimer, M. D., de Swiet, M., Van Assche, A. and Moutquin, J. M. (2001) The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens. Pregnancy 20, IX-XIV
2. Sibai, B. M., Dekker, G. and Kupferminc, M. (2005) Pre-eclampsia. Lancet 365, 785-799
3. Roberts, J. M. and Cooper, D.W. (2001) Pathogenesis and genetics of pre-eclampsia. Lancet 357, 53-56
4. Ganzevoort, W., Rep, A., de Vries, J. I., Bonsel, G. J. and Wolf, H. (2006) Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 195, 495-503
5. Zhang, J., Klebanoff, M. A. and Roberts, J. M. (2001) Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet. Gynecol. 97, 261-267
6. von Dadelszen, P., Payne, B., Li, J., Ansermino, J. M., Broughton Pipkin, F., Cote, A. M., Douglas, M. J., Gruslin, A., Hutcheon, J. A., Joseph, K. S. et al. (2011) Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 377, 219-227
7. Kupferminc, M. J., Daniel, Y., Englender, T., Baram, A., Many, A., Jaffa, A. J., Gull, I. and Lessing, J. B. (1997) Vascular endothelial growth factor is increased in patients with preeclampsia. Am. J. Reprod. Immunol. 38, 302-306
8. Venkatesha, S., Toporsian, M., Lam, C., Hanai, J., Mammoto, T., Kim, Y. M., Bdolah, Y., Lim, K. H., Yuan, H. T., Libermann, T. A. et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649
9. Torry, D. S., Wang, H. S., Wang, T. H., Caudle, M. R. and Torry, R. J. (1998) Preeclampsia is associated with reduced serum levels of placenta growth factor. Am. J. Obstet. Gynecol. 179, 1539-1544
10. Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
11. Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R., Thadhani, R. and Karumanchi, S. A. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355, 992-1005
12. Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H. et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683
13. Schiettecatte, J., Russcher, H., Anckaert, E., Mees, M., Leeser, B., Tirelli, A. S., Fiedler, G. M., Luthe, H., Denk, B. and Smitz, J. (2010) Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin. Biochem. 43, 768-770
14. Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M. G., Pape, J., Dudenhausen, J.W., Denk, B. and Stepan, H. (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 202, e1-e11
15. Sunderji, S., Gaziano, E., Wothe, D., Rogers, L. C., Sibai, B., Karumanchi, S. A. and Hodges-Savola, C. (2009) Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am. J. Obstet. Gynecol.
16. Robertson,W. B., Brosens, I. and Dixon, H. G. (1967) The pathological response of the vessels of the placental bed to hypertensive pregnancy. J. Pathol. Bacteriol, 93, 581-592
17. Brosens, I. A., Robertson, W. B. and Dixon, H. G. (1972) The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet. Gynecol. Annu. 1, 177-191
18. Kaufmann, P., Bruns, U., Leiser, R., Luckhardt, M. and Winterhager, E. (1985) The fetal vascularisation of term human placental villi. II. Intermediate and terminal villi. Anat. Embryol. 173, 203-214
19. Leiser, R., Luckhardt, M., Kaufmann, P., Winterhager, E. and Bruns, U. (1985) The fetal vascularisation of term human placental villi. I. Peripheral stem villi. Anat. Embryol. 173, 71-80
20. Genbacev, O., Zhou, Y., Ludlow, J.W. and Fisher, S. J. (1997) Regulation of human placental development by oxygen tension. Science, 277, 1669-1672
21. Zhou, Y., Genbacev, O., Damsky, C. H. and Fisher, S. J. (1998) Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. J. Reprod. Immunol. 39, 197-213
22. Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845
23. Gerber, H. P., Condorelli, F., Park, J. and Ferrara, N. (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272, 23659-23667
24. Nagamatsu, T., Fujii, T., Kusumi, M., Zou, L., Yamashita, T., Osuga, Y., Momoeda, M., Kozuma, S. and Taketani, Y. (2004) Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145, 4838-4845
25. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S.W., Koos, R. D. and Semenza, G. L. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol, 16, 4604-4613
26. Rajakumar, A., Doty, K., Daftary, A., Harger, G. and Conrad, K. P. (2003) Impaired oxygen-dependent reduction of HIF-1α and -2α proteins in pre-eclamptic placentae. Placenta 24, 199-208
27. 3. J. Clin. Invest. 105, 577-587
28. Nevo, O., Soleymanlou, N., Wu, Y., Xu, J., Kingdom, J., Many, A., Zamudio, S. and Caniggia, I. (2006) Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R1085-R1093
29. Lash, G. E.,Cartwright, J. E.,Whitley, G. S., Trew, A. J. and Baker, P. N. (1999) The effects of angiogenic growth factors on extravillous trophoblast invasion and motility. Placenta 20, 661-667
30. Lash, G. E., Warren, A. Y., Underwood, S. and Baker, P. N. (2003) Vascular endothelial growth factor is a chemoattractant for trophoblast cells. Placenta 24, 549-556
31. Crocker, I. P., Strachan, B. K., Lash, G. E., Cooper, S., Warren, A. Y. and Baker, P. N. (2001) Vascular endothelial growth factor but not placental growth factor promotes trophoblast syncytialization in vitro. J. Soc. Gynecol. Investig. 8, 341-346
32. Brockelsby, J., Hayman, R., Ahmed, A., Warren, A., Johnson, I. and Baker, P. (1999) VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia. Lab. Invest. 79, 1101-1111
33. Hayman, R., Warren, A., Brockelsby, J., Johnson, I. and Baker, P. (2000) Plasma from women with pre-eclampsia induces an in vitro alteration in the endotheliumdependent behaviour of myometrial resistance arteries. Br. J. Obstet. Gyncaecol. 107, 108-115
34. Li, Z., Zhang, Y., Ying Ma, J., Kapoun, A. M., Shao, Q., Kerr, I., Lam, A., O'Young, G., Sannajust, F., Stathis, P. et al. (2007) Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686-692
35. Makris, A., Thornton, C., Thompson, J., Thomson, S., Martin, R., Ogle, R., Waugh, R., McKenzie, P., Kirwan, P. and Hennessy, A. (2007) Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71, 977-984
36. Sela, S., Itin, A., Natanson-Yaron, S., Greenfield, C., Goldman-Wohl, D., Yagel, S. and Keshet, E. (2008) A novel human-specific soluble vascular endothelial growth factor receptor 1: cell type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102, 1566-1574
37. Thomas, C. P., Andrews, J. I., Raikwar, N. S., Kelley, E. A., Herse, F., Dechend, R., Golos, T. G. and Liu, K. Z. (2009) A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J. Clin. Endocrinol. Metabol. 94, 2524-2530
38. Ribatti, D. (2008) The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 11, 215-221
39. Geusens, N., Hering, L., Verlohren, S., Luyten, C., Drijkoningen, K., Taube, M., Vercruysse, L., Hanssens, M., Dechend, R. and Pijnenborg, R. (2010) Changes in endovascular trophoblast invasion and spiral artery remodelling at term in a transgenic preeclamptic rat model. Placenta 31, 320-326
40. Verlohren, S., Geusens, N., Morton, J., Verhaegen, I., Hering, L., Herse, F., Dudenhausen, J. W., Muller, D. N., Luft, F. C., Cartwright, J. E. et al. (2010) Inhibition of trophoblast-induced spiral artery remodeling reduces placental perfusion in rat pregnancy. Hypertension 56, 304-310
41. Caluwaerts, S., Vercruysse, L., Luyten, C. and Pijnenborg, R. (2005) Endovascular trophoblast invasion and associated structural changes in uterine spiral arteries of the pregnant rat. Placenta 26, 574-584
42. Bills, V. L., Varet, J., Millar, A., Harper, S. J., Soothill, P. W. and Bates, D. O. (2009) Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin. Sci. 116, 265-272
43. Bates, D. O., MacMillan, P. P., Manjaly, J. G., Qiu, Y., Hudson, S. J., Bevan, H. S., Hunter, A. J., Soothill, P. W., Read, M., Donaldson, L. F. and Harper, S. J. (2006) The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clin. Sci. 110, 575-585
44. Lamarca, B.,Wallukat, G., Llinas, M., Herse, F., Dechend, R. and Granger, J. P. (2008) Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor α in pregnant rats. Hypertension 52, 1168-1172
45. Gilbert, J. S., Babcock, S. A. and Granger, J. P. (2007) Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142-1147
46. Dragun, D., Muller, D. N., Brasen, J. H., Fritsche, L., Nieminen-Kelha, M., Dechend, R., Kintscher, U., Rudolph, B., Hoebeke, J., Eckert, D. et al. (2005) Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352, 558-569
47. Wallukat, G., Homuth, V., Fischer, T., Lindschau, C., Horstkamp, B., Jupner, A., Baur, E., Nissen, E., Vetter, K., Neichel, D. et al. (1999) Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103, 945-952
48. Dechend, R., Viedt, C., Muller, D. N., Ugele, B., Brandes, R. P., Wallukat, G., Park, J. K., Janke, J., Barta, P., Theuer, J. et al. (2003) AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107, 1632-1639
49. Dechend, R., Homuth, V., Wallukat, G., Kreuzer, J., Park, J. K., Theuer, J., Juepner, A., Gulba, D. C., Mackman, N., Haller, H. and Luft, F. C. (2000) AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation, 101, 2382-2387
50. Herse, F., Dechend, R., Harsem, N. K., Wallukat, G., Janke, J., Quadri, F., Hering, L., Muller, D. N., Luft, F. C. and Staff, A. C. (2007) Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 49, 604-611
51. Gant, N. F., Daley, G. L., Chand, S., Whalley, P. J. and MacDonald, P. C. (1973) A study of angiotensin II pressor response throughout primigravid pregnancy. J. Clin. Invest. 52, 2682-2689
52. Baylis, C., Beinder, E., Suto, T. and August, P. (1998) Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy. Semin. Nephrol. 18, 208-230
53. Zhou, C. C., Zhang, Y., Irani, R. A., Zhang, H., Mi, T., Popek, E. J., Hicks, M. J., Ramin, S. M., Kellems, R. E. and Xia, Y. (2008) Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med. 14, 855-862
54. Zhou, C. C., Ahmad, S., Mi, T., Abbasi, S., Xia, L., Day, M. C., Ramin, S. M., Ahmed, A., Kellems, R. E. and Xia, Y. (2008) Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 51, 1010-1019
55. Verlohren, S., Niehoff, M., Hering, L., Geusens, N., Herse, F., Tintu, A. N., Plagemann, A., LeNoble, F., Pijnenborg, R., Muller, D. N. et al. (2008) Uterine vascular function in a transgenic preeclampsia rat model. Hypertension 51, 547-553
56. Roberts, J. M., Taylor, R. N., Musci, T. J., Rodgers, G. M., Hubel, C. A. and McLaughlin, M. K. (1989) Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161, 1200-1204
57. Roberts, J. M., Taylor, R. N. and Goldfien, A. (1991) Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am. J. Hypertens, 4, 700-708
58. Savvidou, M. D., Hingorani, A. D., Tsikas, D., Frolich, J. C., Vallance, P. and Nicolaides, K. H. (2003) Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361, 1511-1517
59. Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H. and Quaggin, S. E. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716
60. Eremina, V., Cui, S., Gerber, H., Ferrara, N., Haigh, J., Nagy, A., Ema, M., Rossant, J., Jothy, S., Miner, J. H. and Quaggin, S. E. (2006) Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol. 17, 724-735
61. Kuenen, B. C., Levi, M., Meijers, J. C., Kakkar, A. K., van Hinsbergh, V. W., Kostense, P. J., Pinedo, H. M. and Hoekman, K. (2002) Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 22, 1500-1505
62. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X. and Rosenberg, S. A. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434
63. Lyall, F., Young, A., Boswell, F., Kingdom, J. C. and Greer, I. A. (1997) Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta 18, 269-276
64. Cooper, J. C., Sharkey, A. M., Charnock-Jones, D. S., Palmer, C. R. and Smith, S. K. (1996) VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br. J. Obstet. Gynaecol, 103, 1191-1196
65. Bosio, P. M., Wheeler, T., Anthony, F., Conroy, R., O'Herlihy, C. and McKenna, P. (2001) Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am. J. Obstet. Gynecol. 184, 146-152
66. Baker, P. N., Krasnow, J., Roberts, J. M. and Yeo, K. T. (1995) Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet. Gynecol. 86, 815-821
67. Livingston, J. C., Chin, R., Haddad, B., McKinney, E. T., Ahokas, R. and Sibai, B. M. (2000) Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am. J. Obstet. Gynecol. 183, 1554-1557
68. Lyall, F., Greer, I. A., Boswell, F. and Fleming, R. (1997) Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br. J. Obstet. Gynaecol. 104, 223-228
69. Reuvekamp, A., Velsing-Aarts, F. V., Poulina, I. E., Capello, J. J. and Duits, A. J. (1999) Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br. J. Obstet. Gynaecol. 106, 1019-1022
70. Chaiworapongsa, T., Espinoza, J., Gotsch, F., Kim, Y. M., Kim, G. J., Goncalves, L. F., Edwin, S., Kusanovic, J. P., Erez, O., Than, N. G. et al. (2008) The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J. Matern. Fetal Neonatal Med. 21, 25-40
71. Boutsikou, T., Malamitsi-Puchner, A., Economou, E., Boutsikou, M., Puchner, K. P. and Hassiakos, D. (2006) Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum. Dev. 82, 235-239
72. Malamitsi-Puchner, A., Boutsikou, T., Economou, E., Sarandakou, A.,Makrakis, E., Hassiakos, D. and Creatsas, G. (2005) Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm. 2005, 293-297
73. Shibata, E., Rajakumar, A., Powers, R. W., Larkin, R. W., Gilmour, C., Bodnar, L. M., Crombleholme, W. R., Ness, R. B., Roberts, J. M. and Hubel, C. A. (2005) Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-forgestational-age neonates: relationship to circulating placental growth factor. J. Clin. Endocrinol. Metab. 90, 4895-4903
74. Wath́en, K.-A., Tuutti, E., Stenman, U.-H., Alfthan, H., Halmesm̈aki, E., Finne, P., Ylikorkala, O. and Vuorela, P. (2006) Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin. Endocrinol. Metab. 91, 180-184
75. Espinoza, J., Romero, R., Nien, J. K., Kusanovic, J. P., Richani, K., Gomez, R., Kim, C. J., Mittal, P., Gotsh, F., Erez, O. et al. (2006) A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J. Matern. Fetal Neonatal Med. 19, 607-613
76. Kusanovic, J. P., Romero, R., Espinoza, J., Nien, J. K., Kim, C. J., Mittal, P., Edwin, S., Erez, O., Gotsch, F., Mazaki-Tovi, S. et al. (2008) Twin-to-twin transfusion syndrome: an antiangiogenic state? Am. J. Obstet. Gynecol. 198, 382 e1-e8
77. Signore, C., Mills, J. L., Qian, C., Yu, K., Lam, C., Epstein, F. H., Karumanchi, S. A. and Levine, R. J. (2006) Circulating angiogenic factors and placental abruption. Obstet. Gynecol. 108, 338-344
78. Espinoza, J., Chaiworapongsa, T., Romero, R., Kim, Y. M., Kim, G. J., Nien, J. K., Kusanovic, J. P., Erez, O., Bujold, E., Gonçalves, L. F. et al. (2007) Unexplained fetal death: another anti-angiogenic state. J. Matern. Fetal Neonatal Med. 20, 495-507
79. Harrington, K. F., Campbell, S., Bewley, S. and Bower, S. (1991) Doppler velocimetry studies of the uterine artery in the early prediction of pre-eclampsia and intra-uterine growth retardation. Eur. J. Obstet. Gynecol. Reprod. Biol. 42 (Suppl.), S14-S20
80. Spencer, K., Yu, C.K.H., Savvidou, M., Papageorghiou, A. T. and Nicolaides, K. H. (2006) Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free β-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet. Gynecol. 27, 658-663
81. Papageorghiou, A. T., Yu, C. K., Cicero, S., Bower, S. and Nicolaides, K. H. (2002) Second-trimester uterine artery Doppler screening in unselected populations: a review. J. Matern. Fetal Neonatal Med. 12, 78-88
82. Chien, P. F., Arnott, N., Gordon, A., Owen, P. and Khan, K. S. (2000) How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview. Br. J. Obstet. Gynecol. 107, 196-208
83. Parra, M., Rodrigo, R., Barja, P., Bosco, C., Ferńandez, V., Mũnoz, H. and Soto-Chaćon, E. (2005) Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am. J. Obstet. Gynecol. 193, 1486-1491
84. Stepan, H., Geipel, A., Schwarz, F., Kramer, T.,Wessel, N. and Faber, R. (2008) Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol. 198, 175 e1-e6
85. Schlembach, D., Wallner, W., Sengenberger, R., Stiegler, E., Mortl, M., Beckmann, M. W. and Lang, U. (2007) Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet. Gynecol. 29, 407-413
86. Stepan, H., Unversucht, A., Wessel, N. and Faber, R. (2007) Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49, 818-824
87. Thadhani, R., Mutter, W. P., Wolf, M., Levine, R. J., Taylor, R. N., Sukhatme, V. P., Ecker, J. and Karumanchi, S. A. (2004) First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab. 89, 770-775
88. Baumann, M. U., Bersinger, N. A., Mohaupt, M. G., Raio, L., Gerber, S. and Surbek, D. V. (2008) First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for lateonset preeclampsia. Am. J. Obstet. Gynecol. 199, 266.e1-266.e6
89. Akolekar, R., de Cruz, J., Foidart, J.-M., Munaut, C. and Nicolaides, K. H. (2010) Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat. Diagn. 30, 191-197
90. Foidart, J. M., Schaaps, J. P., Chantraine, F., Munaut, C. and Lorquet, S. (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia: a step forward but not the definitive answer. J. Reprod. Immunol. 82, 106-111
91. Erez, O., Romero, R., Espinoza, J., Fu, W., Todem, D., Kusanovic, J. P., Gotsch, F., Edwin, S., Nien, J. K., Chaiworapongsa, T. et al. (2008) The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J. Matern. Fetal Neonatal Med. 21, 279-287
92. Kusanovic, J. P., Romero, R., Chaiworapongsa, T., Erez, O., Mittal, P., Vaisbuch, E., Mazaki-Tovi, S., Gotsch, F., Edwin, S. S., Gomez, R. et al. (2009) A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 22, 1021-1038
93. Moore Simas, T. A., Crawford, S. L., Solitro, M. J., Frost, S. C., Meyer, B. A. and Maynard, S. E. (2007) Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 197, 244.e1-266.e8
94. Buhimschi, C. S., Norwitz, E. R., Funai, E., Richman, S., Guller, S., Lockwood, C. J. and Buhimschi, I. A. (2005) Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 192, 734-741
95. Espinoza, J., Romero, R., Nien, J. K., Gomez, R., Kusanovic, J. P., Goncalves, L. F., Medina, L., Edwin, S., Hassan, S., Carstens, M. and Gonzalez, R. (2007) Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am. J. Obstet. Gynecol. 196, 326.e1-326.e13
96. Askie, L. M., Duley, L., Henderson-Smart, D. J. and Stewart, L. A. (2007) Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369, 1791-1798
97. Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., Forest, J. C. and Giguere, Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet. Gynecol. 116, 402-414
98. Rumbold, A., Duley, L., Crowther, C. A. and Haslam, R. R. (2008) Antioxidants for preventing pre-eclampsia. Cochrane Database Syst. Rev. CD004227, doi: 10.1002/14651858.CD004227.pub3
99. Williams, P. J., Bulmer, J. N., Innes, B. A. and Broughton Pipkin, F. (2011) Possible roles for folic acid in the regulation of trophoblast invasion and placental development in normal early human pregnancy. Biol. Reprod. 84, 1148-1153
100. Sanderson, M., Sappenfield, W. M., Jespersen, K. M., Liu, Q. and Baker, S. L. (2000) Association between level of delivery hospital and neonatal outcomes among South Carolina Medicaid recipients. Am. J. Obstet. Gynecol. 183, 1504-1511
101. Bode, M. M., O'Shea T, M., Metzguer, K. R. and Stiles, A. D. (2001) Perinatal regionalization and neonatal mortality in North Carolina, 1968-1994. Am. J. Obstet. Gynecol. 184, 1302-1307
102. Committee on Obstetric Practice (2002) Antenatal corticosteroid therapy for fetal maturation. American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 78, 95-97
103. Duley, L. and Farrell, B. (2002) Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebocontrolled trial. Lancet 359, 1877-1890
104. Dekker, G. and Sibai, B. (2001) Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 357, 209-215
105. Hadker, N., Garg, S., Costanzo, C., Miller, J. D., Foster, T., van der Helm, W. and Creeden, J. (2010) Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J. Med. Econ. 13, 728-737